Gut-brain research opens a new line of inquiry in canine epilepsy

Interest in the gut-brain axis as a tool in canine epilepsy management is gaining traction, as new and emerging veterinary research points to measurable microbiome differences in dogs with idiopathic epilepsy. A 2025 Animal Microbiome study comparing 19 drug-naive epileptic dogs with 17 healthy controls found reduced bacterial richness in epileptic dogs, along with lower levels of short-chain-fatty-acid-producing genera such as Faecalibacterium, Prevotella, and Blautia, and higher levels of Escherichia coli and Clostridium perfringens. The findings add weight to a broader conversation, reflected in Vet Candy Radio’s recent coverage, that dysbiosis may influence seizure activity through immune, metabolic, and neuroinflammatory pathways rather than serving as a simple gastrointestinal side note. (animalmicrobiome.biomedcentral.com)

Why it matters: For veterinary professionals, the key takeaway is that microbiome-directed strategies are still adjunctive, not replacement therapy. Early clinical work presented at ACVIM Forum in June 2024 found a numerical drop in mean seizure frequency during a probiotic phase in dogs already receiving anti-epileptic drugs, but the difference was not statistically significant, and the sample was small. That leaves clinicians with a promising but still preliminary evidence base: diet history, gastrointestinal health, antimicrobial exposure, and client discussions about supplements may deserve more attention in epilepsy workups, but anticonvulsants remain the standard of care. (dvm360.com)

What to watch: Watch for larger controlled trials, microbiome profiling work, and studies testing probiotics, diet changes, or fecal microbiota transplantation as add-ons for drug-resistant canine epilepsy. (dvm360.com)